New analysis from GlobalData spans the growth of the heart failure market across seven major markets including the US, Europe ...

Newer therapies for multiple conditions were major stories this year, but long-term HF survival gains seem to have vanished.

(Balcinrenone + dapagliflozin) is under clinical development by AstraZeneca and currently in Phase II for Proteinuria.

AR = Androgen receptor; ER = Estrogen receptor; GR = Glucocorticoid receptor; MR = Mineralocorticoid receptor; PR = Progesterone receptor. The relative binding affinity (%) of the main progestins ...

Drospirenone (Slynd, Slinda, Lyzbet) is a synthetic spironolactone analogue with anti-mineralocorticoid activity. It is formulated as film coated tablets and coated tablets, tablets for oral route of ...

Berlin: Bayer has announced the submission of marketing authorization applications to the U.S. Food and Drug Administration ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

Ideally, steroidal mineralocorticoid receptor antagonists such as spironolactone and eplerenone would be more widely prescribed; however, concerns of hyperkalemia and hormonal adverse effects ...

The Danish group bought rights to ocedurenone, an oral non-steroidal mineralocorticoid receptor antagonist (nsMRA), from the Singapore biotech in October 2023 as a companion to its GLP-1-based ...